Towards the understanding of the UV light, riboflavin and additive solution contributions to the in vitro lesions observed in Mirasol®-treated platelets

Transfus Clin Biol. 2019 Nov;26(4):209-216. doi: 10.1016/j.tracli.2019.09.001. Epub 2019 Sep 18.

Abstract

Objectives: Pathogen reduction technologies are implemented to increase the safety of blood products. We previously showed that the UVB alone significantly contributes to the storage lesions observed in platelets treated with riboflavin/UVB using a home-made illuminator. The present study aims at confirming these observations using the commercial Mirasol® technology.

Methods: A three-arm study (untreated, UV-, Mirasol®-treated platelets) was conducted to investigate the platelet storage lesions throughout storage (n=4). A two-arm study was then designed to compare Intersol and T-PAS+ additive solutions (n=3). Phenotype and functional platelet characteristics were assessed using flow cytometry, aggregometry, antioxidant assays and metabolic parameters.

Results: Mirasol®-treated platelets exhibit enhanced storage lesions compared to controls (increase of activation markers and glycolysis rate, lower hypotonic shock and double-agonist activation responses, and decrease of total antioxidant capacity). Here, we also confirmed that the UV radiation alone is causing platelet lesions. Riboflavin tends to have an intracellular protective role while it decreases the extracellular antioxidant defenses. Furthermore, benefits of platelet additive solutions containing potassium and magnesium were confirmed as it reduces the extent of storage lesions.

Conclusions: The photosensitizer, UV illumination and composition of the platelet additive solutions are key parameters influencing the platelet storage lesion. The clinical relevance of these findings is not fully understood and recent published clinical studies could not show increase in bleeding in patients receiving Mirasol-treated platelets. New developments in storage solutions might help to improve storage conditions of PRT-treated platelets and should be prioritised as research subject in the future.

Keywords: Additive solution; Inactivation des pathogènes; Lésion de stockage; Pathogen inactivation; Pathogen reduction; Platelet storage lesion; Riboflavin; Riboflavine; Réduction des pathogènes; Solution additive.

Publication types

  • Comparative Study

MeSH terms

  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Blood Platelets / radiation effects*
  • Blood Preservation / methods
  • Blood Proteins / analysis
  • Blood Safety
  • Blood-Borne Pathogens / drug effects
  • Blood-Borne Pathogens / radiation effects
  • Epinephrine / pharmacology
  • Humans
  • Organ Preservation Solutions / pharmacology*
  • Osmotic Pressure
  • Phosphates / pharmacology
  • Photosensitizing Agents / pharmacology*
  • Platelet Aggregation / drug effects
  • Platelet-Rich Plasma
  • Potassium Chloride / pharmacology
  • Riboflavin / pharmacology*
  • Riboflavin / radiation effects
  • Sodium / pharmacology
  • Sodium Acetate / pharmacology
  • Sodium Chloride / pharmacology
  • Sodium Citrate / pharmacology
  • Ultraviolet Rays / adverse effects*

Substances

  • Blood Proteins
  • Organ Preservation Solutions
  • Phosphates
  • Photosensitizing Agents
  • Sodium Citrate
  • Sodium Chloride
  • Sodium Acetate
  • Potassium Chloride
  • Sodium
  • sodium phosphate
  • Riboflavin
  • Epinephrine